89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in the following upcoming investor conferences in June:

  • SVB Leerink CybeRx Series: Liver Disease Day

    Format: One-on-one investor meetings

    Date: Thursday, June 17, 2021
  • Raymond James Human Health Innovation Conference

    Panel Discussion: "State" of the Union: Current Thinking in NASH

    Date: Wednesday, June 23, 2021 at 12:00 PM ET
  • Piper Sandler EASL Takeaway Day

    Format: One-on-one investor meetings

    Date: Monday, June 28, 2021

About 89bio

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:

Ryan Martins

Chief Financial Officer

investors@89bio.com

Media Contact:

Peter Duckler

773-343-3069

pduckler@w2ogroup.com



Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!